Mn(III) porphyrins as potential MRI contrast agents for diagnosis and MRI-guided therapy

Carlos F.G.C. Geraldes*, M. Margarida C.A. Castro, Joop A. Peters

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)


Mn(III) porphyrins have great potential as Gd-free MRI contrast agents because both the cation and the ligand have interesting properties. The redox properties of the Mn(III)-ion can be exploited for the preparation of reactive oxygen species for therapy. Moreover, the porphyrin ligand allows these complexes to have a high affinity for tumor tissues. The inherent properties of the porphyrin ligands make these systems attractive for photothermal, photodynamic, and sonodynamic therapies. Therefore, these systems are attractive for the development of theranostics for MRI-guided therapy. For the magnetic field strengths at which most clinical MRI machines operate at present (0.5–1.5 T), the longitudinal relativity of low-molecular-weight complexes is even higher than that of the classical Gd-based contrast agents. This review gives an overview of the developments in the field of Mn(III) porphyrin contrast agents during the last 30 years.

Original languageEnglish
Article number214069
JournalCoordination Chemistry Reviews
Publication statusPublished - 2021

Bibliographical note

Accepted Author Manuscript


  • Chemotherapy
  • Photodynamic therapy
  • Photothermal therapy
  • Relaxivity
  • Theranostics


Dive into the research topics of 'Mn(III) porphyrins as potential MRI contrast agents for diagnosis and MRI-guided therapy'. Together they form a unique fingerprint.

Cite this